Leading the way in innovation for over 50 years, we build greater futures for businesses across multiple industries and 131 countries.
Our expert, committed team put our shared beliefs into action – every day. Together, we combine innovation and collective knowledge to create the extraordinary.
We share news, insights, analysis and research – tailored to your unique interests – to help you deepen your knowledge and impact.
At TCS, we believe exceptional work begins with hiring, celebrating and nurturing the best people — from all walks of life.
Matthew Moyer, Director - Operations and supply tech, Merck, and Narayanan R., Chief Architect - TCS ADD™, discuss and demonstrate approaches and real-life examples to enable patient-centric trials through a unified, integrated platform.
Highlights
Enabling patient-centric trials
Clinical trials have been primarily driven by a site-centric approach (such as face-to-face interactions at the site).
The COVID-19 pandemic severely impacted the functioning of traditional clinical trials and opened a world of possibilities to move to the next generation of clinical trials. Augmented by digital technologies, clinical trials improve participant access, engagement enabling patient-centricity.
Merck partnered with TCS to realize its vision of a digitally enabled trials platform (DETP), leveraging TCS ADD’s decentralized trials solution. The DETP was aimed at resolving challenges around protocol impact, supplier qualification and GxP procedures, managing data privacy, and calculating RoI.
The partnership facilitated a host of features being actively tested, viz-a-viz, electronic date capture from device and reporting, auto reminders, interim data storage, API, passive data transfer, and BYOD.
Integrated ecosystems are key to better patient outcomes.
Talk to our expertsFind out more
